Comparison of GnRH agonists and antagonists in normoresponder IVF/ICSI in Turkish female patients

Abstract

GnRHant and GnRHa provide comparable results in normoresponder patients, while GnRHant allows a greater flexibility in their treatment.

Follicular growth and oocyte maturation in GnRH agonist and antagonist protocols forin vitrofertilisation and embryo transfer

“…Several authors [20,32,33] reported a significant decrease in pregnancy rate for the antagonist compared to the agonist, although many clinical studies [34,35] have reported no differences in pregnancy rates between the antagonist and agonist groups, In conclusion, because the numbers of collected oocytes and mature oocytes are good parameters qualifying follicular maturation, our overall data seem to reflect a better follicular growth and oocyte maturation after triptorelin treatment. However, both regimens seem to have similar efficacy in terms of implantation and pregnancy rates, as reported by other authors [10,36,37]. The role of GnRH antagonists in ovarian stimulation for IVF appears to be promising, although many questions regarding preferred dose regimens and effects on clinical outcomes remain.…”

Effect of Total versus Partial Assisted Hatching on the Clinical Pregnancy Rates in Assisted Reproduction Technology

“…Some methods have been suggested for AH such as mechanically, by laser energy, or chemically, by acid solution methods (22). Following introduction of the best technique to be laser AH, studies started to investigate the partial or total zona hatching on the ART outcome (23)(24)(25)(26). Additional studies on the frozen-thawed embryo cycles revealed variable results (27,28).…”

“…For all participants with the first cycle without known poor prognosis, a gonadotropin-releasing hormone antagonist protocol was used for in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) (23). On the second day of the menstrual cycle, 150-300 IU of recombinant follicle-stimulating hormone (r-FSH) (Gonal-F™, Merck-Serono, Geneva, Switzerland) were administered, and mean follicular growth was monitored via two-dimensional trans-vaginal sonography (TVS).…”

Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression

“…More recently GnRH antagonists were introduced for the same purpose, and the efficient dose is reported to be 0.25 mg, administered daily (2,18). Initially, GnRH antagonists were related to lower PRs and implantation rates (19)(20)(21)(22), but recent studies did not confirm this finding (23)(24)(25)(26), especially when care was taken to avoid prolongation of the follicular phase and initiation of ovarian stimulation with high P levels (27,28).…”